IGF-1 LR3 is a long-acting synthetic IGF-1 analogue used in the community mainly for muscle growth and hyperplasia, with a smaller set of reports around body recomposition, fat loss, and recovery. People most commonly run 50 mcg a day, mostly daily, though reported doses stretch from 20 mcg all the way to 10 mg; clinician protocols land at 100 mcg twice daily by subcutaneous injection over four-to-six-week cycles. The honest caveat is that there is no FDA-approved indication, the human evidence is preclinical and animal-only, and all use is off-label or compounded.
Data last updated
Measured on 3 of 6 axes
Evidence shape
IGF-1 LR3 currently exists as an animal-only research tool with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic research, providing no data on safety or efficacy in human subjects. Because there are zero registered trials and no completed human studies, the evidence base for this peptide remains entirely theoretical and lacks the necessary oversight to support clinical application.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How IGF-1 LR3 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community reports use IGF‑1 LR3 daily, typically around 100 µg (reported range 30 µg–10 mg), while a smaller group dose three times per week at about 1 mg (1–3 mg) or weekly at 500 µg; no cycling is described.